JP2025041678A5 - - Google Patents

Info

Publication number
JP2025041678A5
JP2025041678A5 JP2024212437A JP2024212437A JP2025041678A5 JP 2025041678 A5 JP2025041678 A5 JP 2025041678A5 JP 2024212437 A JP2024212437 A JP 2024212437A JP 2024212437 A JP2024212437 A JP 2024212437A JP 2025041678 A5 JP2025041678 A5 JP 2025041678A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024212437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025041678A (ja
Filing date
Publication date
Priority claimed from PCT/GB2019/052980 external-priority patent/WO2020079448A1/en
Application filed filed Critical
Publication of JP2025041678A publication Critical patent/JP2025041678A/ja
Publication of JP2025041678A5 publication Critical patent/JP2025041678A5/ja
Pending legal-status Critical Current

Links

JP2024212437A 2018-10-19 2024-12-05 新規な癌抗原及び方法 Pending JP2025041678A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18201634.5 2018-10-19
EP18201634 2018-10-19
PCT/GB2019/052980 WO2020079448A1 (en) 2018-10-19 2019-10-18 Novel cancer antigens and methods
JP2021546487A JP7712207B2 (ja) 2018-10-19 2019-10-18 新規な癌抗原及び方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021546487A Division JP7712207B2 (ja) 2018-10-19 2019-10-18 新規な癌抗原及び方法

Publications (2)

Publication Number Publication Date
JP2025041678A JP2025041678A (ja) 2025-03-26
JP2025041678A5 true JP2025041678A5 (enExample) 2025-07-17

Family

ID=64183836

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021546487A Active JP7712207B2 (ja) 2018-10-19 2019-10-18 新規な癌抗原及び方法
JP2022173369A Active JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A Pending JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021546487A Active JP7712207B2 (ja) 2018-10-19 2019-10-18 新規な癌抗原及び方法
JP2022173369A Active JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法

Country Status (12)

Country Link
US (2) US12263216B2 (enExample)
EP (1) EP3866827A1 (enExample)
JP (3) JP7712207B2 (enExample)
KR (1) KR20210080372A (enExample)
CN (2) CN119978090A (enExample)
AU (1) AU2019360427A1 (enExample)
BR (1) BR112021006941A2 (enExample)
CA (1) CA3112427A1 (enExample)
EA (1) EA202191081A1 (enExample)
IL (1) IL282308A (enExample)
MX (1) MX2021004453A (enExample)
WO (1) WO2020079448A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7712207B2 (ja) 2018-10-19 2025-07-23 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
AU2020302285A1 (en) * 2019-06-28 2021-12-02 Enara Bio Limited Novel cancer antigens and methods
CN116057067A (zh) * 2020-04-17 2023-05-02 弗朗西斯·克里克研究所有限公司 用于治疗黑素瘤的ctl抗原的融合蛋白
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US7504490B1 (en) 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
WO2001064835A2 (en) 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001249922A1 (en) 2000-04-06 2001-10-23 Pharmacia And Upjohn Company G protein-coupled receptors
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP2003304877A (ja) 2002-04-15 2003-10-28 Keio Gijuku ヒト色素細胞特異分子
WO2004038003A2 (en) 2002-10-25 2004-05-06 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
WO2006103562A2 (en) 2005-03-30 2006-10-05 Centre National De La Recherche Scientifique (Cnrs) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2032162A2 (en) 2006-05-22 2009-03-11 Board of Regents, The University of Texas System Herv-k antigens, antibodies, and methods
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
CA2676090A1 (en) 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
US8541553B2 (en) 2007-05-24 2013-09-24 Baxter Healthcare Sa Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
WO2009026116A2 (en) 2007-08-16 2009-02-26 Genizon Biosciences, Inc. Genemap of the human genes associated with longevity
WO2009039244A2 (en) 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
US8323659B2 (en) 2008-09-18 2012-12-04 Keio University Method for diagnosing and/or treating tumor
CA2847290A1 (en) 2011-08-30 2013-03-07 Dcb-Usa Llc Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
FR2984362B1 (fr) 2011-12-20 2017-11-24 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer du poumon
WO2014004385A2 (en) 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines
WO2016094420A1 (en) 2014-12-08 2016-06-16 The Regents Of The University Of Michigan Non-coding rnas and uses thereof
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
CR20200607A (es) 2016-04-21 2021-01-20 Immatics Biotechnologies Gmbh INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-551)
CN110505877A (zh) 2017-02-01 2019-11-26 摩登纳特斯有限公司 Rna癌症疫苗
JP7712207B2 (ja) 2018-10-19 2025-07-23 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
AU2020302285A1 (en) 2019-06-28 2021-12-02 Enara Bio Limited Novel cancer antigens and methods
KR20220029560A (ko) 2019-06-28 2022-03-08 더 프란시스 크릭 인스티튜트 리미티드 신규한 암 항원 및 방법
JP2022539585A (ja) 2019-07-05 2022-09-12 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
WO2021005338A2 (en) 2019-07-05 2021-01-14 The Francis Crick Institute Limited Novel cancer antigens and methods

Similar Documents

Publication Publication Date Title
JP2024156852A5 (enExample)
JP2024133471A5 (enExample)
JP2023113641A5 (enExample)
JP2024037765A5 (enExample)
JP2025106258A5 (enExample)
JP2025023938A5 (enExample)
JP2023164986A5 (enExample)
JP2024156705A5 (enExample)
JP2025118771A5 (enExample)
JP2025038009A5 (enExample)
JP2023134519A5 (enExample)
JP2025165966A5 (enExample)
JP2023103231A5 (enExample)
JP2023139025A5 (enExample)
JP2025124655A5 (enExample)
JP2025041678A5 (enExample)
JP2024160274A5 (enExample)
JP2024038101A5 (enExample)
JP2018100276A5 (enExample)
JP2022166039A5 (enExample)
JP2018101814A5 (enExample)
JP2023166412A5 (enExample)
EP4003572A4 (en) TEXTURED SORBENT SHEETS, ASSEMBLIES CONTAINING THEM, AND MOLDS FOR THE MANUFACTURE THEREOF
JP2024026218A5 (enExample)
JP2023100679A5 (enExample)